MedTrace Logo

Neonatal Screening of Severe Combined Immunodeficiencies

NCT02590328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180000

Last updated 2022-01-05

No results posted yet for this study

Summary

The goal of the proposed research is to observe the prevalence and establish the validity of a newborn screening method for severe combined immunodeficiency (SCID). The assay to be used is developed on the basis of PCR quantification of T-cell receptor excision circles (TRECs) that is absent in SCID patients, thus correlating with the disease.

Conditions

  • Severe Combined Immunodeficiency
  • Neonatal Screening

Sponsors & Collaborators

  • Children's Hospital of Fudan University

    lead OTHER

Eligibility

Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02590328 on ClinicalTrials.gov